Clinical Trials Logo

Influenza A clinical trials

View clinical trials related to Influenza A.

Filter by:

NCT ID: NCT05567783 Terminated - Influenza A Clinical Trials

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Start date: October 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to <65 years of age without pre-existing risk factors for serious complications from influenza infection.

NCT ID: NCT05354115 Completed - COVID-19 Clinical Trials

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal and nasopharyngeal swabs by the study sponsor, Abbott.

NCT ID: NCT05268939 Completed - COVID-19 Clinical Trials

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

INSPIRE-2
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites. Subjects presenting with symptoms suggestive of COVID-19 and/or Influenza and/or RSV will be consented and asked to donate swab sample(s) for testing in the device(s) under evaluation.

NCT ID: NCT05202379 Completed - Influenza A Clinical Trials

CC-42344 Safety Study in Healthy Participants

Start date: February 11, 2022
Phase: Phase 1
Study type: Interventional

CC-42344 Phase 1 study with single-ascending dose (SAD) and multiple-ascending dose (MAD) parts.

NCT ID: NCT05163730 Completed - COVID-19 Clinical Trials

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This study is designed as a prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal swabs. This study is part of the performance evaluation to support the CE conformity assessment procedures.

NCT ID: NCT04896853 Recruiting - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Start date: May 18, 2021
Phase: Phase 1
Study type: Interventional

To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.

NCT ID: NCT04810949 Terminated - Covid19 Clinical Trials

Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml

Start date: August 5, 2020
Phase: N/A
Study type: Interventional

Scarce information exists in relation to the effect of supplementation of Vitamin D3 in SARS-COV-2 infection, H1N1, and A, B Influenza when 25-hydroxyvitamin levels are between 20-100ng/ml. This study will evaluate the effect of supplementation of vitamin D3 vs. dietary-hygiene measures in SARS-COV-2 , H1N1, A, B Influenza infection rate in patients with serum 25-hydroxyvitamin D3 levels >20ng/ml. A comparative randomized study that will evaluate the effect of a monthly supplementation with 52000 units of Vitamine D3 during three months vs hygienic-dietary measures in the development of respiratory infections such as COVID-19, H1N1, A, B Influenza during 6 months of follow-up in health workers from a hospital in Northern Mexico with serum vitamin D values +/- 20ng/ml. Also, patients that during screening have 25-hydroxyvitamin D3 levels <20 ng/ml will receive vitamin D supplementation according to primary care discretion for three months and will be followed for 6 months and infection rate will be analyzed and compared.

NCT ID: NCT04683406 Completed - Influenza A Clinical Trials

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Start date: December 28, 2020
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.

NCT ID: NCT04653727 Completed - Covid19 Clinical Trials

Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19

AtemNHK
Start date: January 6, 2021
Phase:
Study type: Observational

The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020. Since then, the virus has spread internationally and the WHO has classified the outbreak as a pandemic. In the context of the increasing reporting of this pandemic and the increasing governmental measures to limit or slow down the spread of SARS-CoV-2 by all means, there is so far little scientific evidence for the effects of a healthy lifestyle on the disease. The aim of this study is to compare the potential of different, possibly protective lifestyles using the example of the COVID-19 pandemic. We will conduct an online survey with 3.000 participants using mobile website technology.

NCT ID: NCT04650971 Completed - Influenza A Clinical Trials

Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy Volunteers

Start date: August 29, 2019
Phase: Phase 1
Study type: Interventional

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability, reactogenicity and immunogenic activity of the universal influenza vector vaccine "UniFluVec" at two dose levels after two intranasal administrations in healthy adults. The volunteers randomized to the study group received intranasally 0.5 ml of the vaccine (0.25 ml in each nostril) as nasal aerosol stray twice with an interval of 3 weeks. The vaccine of the first dose level contained 6.7 log EID50/0.5 ml (50% egg infective dose) of attenuated recombinant influenza A/H1N1pdm09 virus; vaccine of the second dose level contained 7.7 log EID50/0.5 ml of attenuated recombinant influenza A/H1N1pdm09 virus. The primary objective of the study was to evaluate the safety, tolerability and reactogenicity profile of vaccine "UniFluVec" based on the frequency and severity of adverse events. The secondary objective of the study was to assess the immunogenicity.